These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30337641)

  • 1. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
    Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
    Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
    Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
    Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
    Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
    Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma.
    Nguyen TT; Torrini C; Shang E; Shu C; Mun JY; Gao Q; Humala N; Akman HO; Zhang G; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
    Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
    Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
    Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
    Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
    Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
    Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
    Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
    Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
    Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.
    Chaudhry S; Beckedorff F; Jasdanwala SS; Totiger TM; Affer M; Lawal AE; Montoya S; Tamiro F; Tonini O; Chirino A; Adams A; Sondhi AK; Noudali S; Cornista AM; Nicholls M; Afaghani J; Robayo P; Bilbao D; Nimer SD; Rodríguez JA; Bhatt S; Wang E; Taylor J
    Leukemia; 2024 Sep; 38(9):1894-1905. PubMed ID: 38997434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
    Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
    J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 20. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.